JP7659653B2 - 疼痛及び炎症性障害の処置 - Google Patents

疼痛及び炎症性障害の処置 Download PDF

Info

Publication number
JP7659653B2
JP7659653B2 JP2023559998A JP2023559998A JP7659653B2 JP 7659653 B2 JP7659653 B2 JP 7659653B2 JP 2023559998 A JP2023559998 A JP 2023559998A JP 2023559998 A JP2023559998 A JP 2023559998A JP 7659653 B2 JP7659653 B2 JP 7659653B2
Authority
JP
Japan
Prior art keywords
pain
polypeptide
bont
seq
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023559998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024509634A (ja
Inventor
カリニチェフ，ミハイル
ペリエ，サンディ
ファーブル，クリスティーヌ
コルネット，シルビー
クルップ，ヨハネス
エリオット，マーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Biopharm Ltd
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Publication of JP2024509634A publication Critical patent/JP2024509634A/ja
Priority to JP2024228411A priority Critical patent/JP2025060836A/ja
Application granted granted Critical
Publication of JP7659653B2 publication Critical patent/JP7659653B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023559998A 2021-03-30 2021-03-30 疼痛及び炎症性障害の処置 Active JP7659653B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024228411A JP2025060836A (ja) 2021-03-30 2024-12-25 疼痛及び炎症性障害の処置

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2021/050783 WO2022208039A1 (en) 2021-03-30 2021-03-30 Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024228411A Division JP2025060836A (ja) 2021-03-30 2024-12-25 疼痛及び炎症性障害の処置

Publications (2)

Publication Number Publication Date
JP2024509634A JP2024509634A (ja) 2024-03-04
JP7659653B2 true JP7659653B2 (ja) 2025-04-09

Family

ID=75396825

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023559998A Active JP7659653B2 (ja) 2021-03-30 2021-03-30 疼痛及び炎症性障害の処置
JP2024228411A Pending JP2025060836A (ja) 2021-03-30 2024-12-25 疼痛及び炎症性障害の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024228411A Pending JP2025060836A (ja) 2021-03-30 2024-12-25 疼痛及び炎症性障害の処置

Country Status (10)

Country Link
US (1) US20250066755A1 (https=)
EP (1) EP4297773A1 (https=)
JP (2) JP7659653B2 (https=)
KR (2) KR20230155007A (https=)
CN (2) CN117396217A (https=)
AU (2) AU2021438810B2 (https=)
BR (1) BR112023018473A2 (https=)
CA (1) CA3211472A1 (https=)
TW (1) TW202304502A (https=)
WO (1) WO2022208039A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023089343A1 (en) * 2021-11-22 2023-05-25 Ipsen Biopharm Limited Treatment of pain

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007511609A (ja) 2003-11-17 2007-05-10 アラーガン、インコーポレイテッド ボツリヌス毒素中毒症を治療するための救出薬剤
WO2020219358A2 (en) 2019-04-17 2020-10-29 Children's Medical Center Corporation Catalytically inactive botulinum neurotoxin-like toxins and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
AU3658093A (en) 1992-02-10 1993-09-03 Seragen, Inc. Desensitization to specific allergens
GB9305735D0 (en) 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
DK1084146T3 (da) 1998-05-13 2003-02-03 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Hybridprotein til inhibering af degranuleringen af mastocyter og anvendelse deraf
ES2205849T3 (es) 1998-07-22 2004-05-01 Osprey Pharmaceuticals Limited Conjugados para tratar alteraciones inflamatorias y asociadas con daños tisulares.
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US6358697B2 (en) 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
HK1046020B (en) 1999-08-25 2007-05-11 Allergan, Inc. Activatable recombinant neurotoxins
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
PL1830872T3 (pl) 2004-12-01 2011-09-30 Sec Dep For Health Białka fuzyjne
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
ES2369558T3 (es) 2005-09-19 2011-12-01 Allergan, Inc. Toxinas clostridiales y toxinas clostridiales activables.
AU2007272515B2 (en) 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
JP2009543558A (ja) 2006-07-11 2009-12-10 アラーガン、インコーポレイテッド 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素
SG10201606666XA (en) 2012-05-30 2016-09-29 Harvard College Engineered Botulinum Neurotoxin
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
CN107108703B (zh) 2015-01-09 2022-09-23 益普生生物创新有限公司 阳离子神经毒素
PT3274364T (pt) 2015-03-26 2021-11-05 Harvard College Neurotoxina botulínica manipulada
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3481852B1 (en) * 2016-07-08 2022-12-07 Children's Medical Center Corporation A novel botulinum neurotoxin and its derivatives
UA128185C2 (uk) 2018-01-29 2024-05-01 Іпсен Біофарм Лімітед Ботулінічний нейротоксин, який розщеплює ненейронний snare
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201914034D0 (en) * 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007511609A (ja) 2003-11-17 2007-05-10 アラーガン、インコーポレイテッド ボツリヌス毒素中毒症を治療するための救出薬剤
WO2020219358A2 (en) 2019-04-17 2020-10-29 Children's Medical Center Corporation Catalytically inactive botulinum neurotoxin-like toxins and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FEBS J.，2011年，vol.278, issue 23，p.4454-4466
J. Biol. Chem.，2011年，vol.286, no.8，p.6375-6385
Toxins，2019年，vol.11, issue 8，459, p.1-24

Also Published As

Publication number Publication date
CN117396217A (zh) 2024-01-12
CA3211472A1 (en) 2022-10-06
CN117396218A (zh) 2024-01-12
AU2021438810A9 (en) 2024-01-04
AU2024227147A1 (en) 2024-10-31
KR20250060320A (ko) 2025-05-07
BR112023018473A2 (pt) 2023-11-14
US20250066755A1 (en) 2025-02-27
AU2021438810B2 (en) 2024-07-18
AU2021438810A1 (en) 2023-09-21
EP4297773A1 (en) 2024-01-03
JP2024509634A (ja) 2024-03-04
WO2022208039A1 (en) 2022-10-06
TW202304502A (zh) 2023-02-01
KR20230155007A (ko) 2023-11-09
JP2025060836A (ja) 2025-04-10

Similar Documents

Publication Publication Date Title
US11248219B2 (en) Fusion proteins comprising a non-cytotoxic protease, a translocation domain, and a targeting moiety that binds a galanin receptor and methods for treating, preventing or ameliorating pain using such fusion proteins
AU2020357905B2 (en) Non-toxic clostridial neurotoxin polypeptides for use in treating neurological disorders
JP2024540579A (ja) 疼痛の治療
US20250195626A1 (en) Treatment of pain & inflammatory disorders
JP2025060836A (ja) 疼痛及び炎症性障害の処置
RU2855485C2 (ru) Каталитически неактивные клостридиальные нейротоксины для лечения боли и воспалительных заболеваний
JP2024540580A (ja) 内臓痛の処置
TW202237176A (zh) 疼痛及發炎性失調之治療
US20240082368A1 (en) Treatment of Brain Damage
RU2859455C2 (ru) Лечение повреждения головного мозга
HK40100217A (zh) 无催化活性的梭菌神经毒素用於疼痛和炎性疾病的治疗
HK40103171A (zh) 疼痛和炎性疾病的治疗
HK40112381A (zh) 内脏疼痛的治疗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231207

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20231207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240625

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250328

R150 Certificate of patent or registration of utility model

Ref document number: 7659653

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150